• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Mitosol Logo

Mitosol®

Mitosol Has It All

  • HOME
  • CONTACT
  • ORDER
  • RESOURCES
    • Mitosol Resource Center
    • The Mitosol Kit
    • What is Mitosol?
    • Getting Started with Mitosol
  • ABOUT US

Order MITOSOL® for your ophthalmic surgical suite today.

Finally, an FDA-approved ophthalmic MMC.

MITOSOLVED. ™

MITOSOL ® has created a new standard of care in glaucoma surgery.

MEET YOUR

NEW STANDARD OF CARE

IN GLAUCOMA SURGERY

The MITOSOL ® KIT for ophthalmic use

The Mitosol Kit
Watch the video

UPGRADE YOUR STANDARD OF CARE – Order MITOSOL® for your ophthalmic surgical suite today.

MITOSOL ® HAS IT ALL

FDA

The only formulation of ophthalmic MMC approved
by the FDA

View Package Insert

USP<800>

The only system to meet new USP<800> standards
for containment and disposal

Download USP<800> Resource

CSTD

Closed-system transfer device minimizes risk of breakage, leakage, and exposure

Watch the Video

MITOSOLVED. ™

Offers an on-demand reconstitution system that’s as immediate as it is precise


Can be stored at room temperature for up to 24 months


Patented, closed-system preparation and disposal

The Mitosol Kit

UPGRADE YOUR STANDARD OF CARE – Order MITOSOL® for your ophthalmic surgical suite today.

THE TOTAL PACKAGE

UPGRADE YOUR STANDARD OF CARE – Order MITOSOL® for your ophthalmic surgical suite today.

MITOSOLVED. ™

The only formulation of ophthalmic MMC that’s:

  • Approved by the FDA
  • Reconstituted on demand, with immediacy and precision
  • USP <800> compliant
  • Room temperature shelf stable for up to 24 months

UPGRADE YOUR STANDARD OF CARE

Order Mitosol
Contact Us

WMI 001 Rev 02/2021

Footer

INDICATION

Mitosol® (mitomycin for solution) 0.2 mg/vial Kit for Ophthalmic Use is an antimetabolite indicated as an adjunct to ab externo glaucoma surgery.

Dosage & Administration

Mitosol® is intended for topical application to the surgical site of glaucoma filtration surgery and must be reconstituted prior to application. Sponges provided within the Mitosol® kit should be fully saturated with the entire reconstituted contents in a manner prescribed in the Instructions For Use. The sponge(s) should be applied to the treatment area for two minutes. Reconstituted Mitosol® should be used within one hour of reconstitution.

US Patents #7,806,265, #8,186,511, #D685,962, #D685,963, #9,205,075, #9,539,241 and #9,649,428; other international patents issued and pending.

Product Information

Please click here for full Product Information for Mitosol®

IMPORTANT SAFETY INFORMATION
Contraindications

Mitosol® is contraindicated in patients that have demonstrated a hypersensitivity to mitomycin in the past.

Warnings & Precautions

Cell Death: Mitomycin is cytotoxic. Use of mitomycin in concentrations higher than 0.2 mg/mL or use for longer than 2 minutes may lead to unintended corneal and/or sclera damage including thinning or perforation. Direct contact with the corneal endothelium will result in cell death. Hypotony: The use of mitomycin has been associated with an increased instance of post-operative hypotony. Cataract Development: Use in phakic patients has been correlated to a higher instance of lenticular change and cataract formation. Embryo-Fetal Toxicity: Can cause fetal harm. Advise of potential risk to a fetus. Verify pregnancy status in females of reproductive potential prior to use.

Adverse Events & Reactions

The most frequent adverse reactions to Mitosol® occur locally and include hypotony, hypotony maculopathy, blebitis, endophthalmitis, vascular reactions, corneal reactions, and cataract. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch, or call 1-800-FDA-1088.

This site is intended only for US residents.
Use of website is governed by the Terms of Use and Privacy Policy
Corporate Responsibility